Clinical Significance of Soluble PD-1 and PD-L1 in Plasma of NSCLC Patients Treated with Immune Checkpoint Inhibitors

被引：0

作者：

Nakahara, Y. ^{[1
]}

Himuro, H. ^{[2
]}

Igarashi, Y. ^{[2
]}

Kouro, T. ^{[2
]}

Higashijima, N. ^{[2
]}

Matsuo, N. ^{[3
]}

Murakami, S.

Wei, F. ^{[2
]}

Horaguchi, S. ^{[2
]}

Tsuji, K. ^{[2
]}

Mano, Y. ^{[2
]}

Saito, H. ^{[4
]}

Azuma, K. ^{[3
]}

Naoki, K.

Sasada, T. ^{[2
]}

机构：

[1] Kitasato Univ, Sch Med, Sagamihara, Kanagawa, Japan

[2] Kanagawa Canc Ctr Res Inst, Yokohama, Kanagawa, Japan

[3] Kurume Univ, Sch Med, Kurume, Fukuoka, Japan

[4] Kanagawa Canc Ctr, Yokohama, Kanagawa, Japan

来源：

JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 11期

关键词：

Immune checkpoint inhibitors; Soluble PD-1; Soluble PD-L1;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

EP11.01-11

引用

页码：S614 / S614

页数：1

共 50 条

[41] The role of PD-1/PD-L1 and application of immune-checkpoint inhibitors in human cancers
Tang, Qing
Chen, Yun
Li, Xiaojuan
Long, Shunqin
Shi, Yao
Yu, Yaya
Wu, Wanyin
Han, Ling
Wang, Sumei
FRONTIERS IN IMMUNOLOGY, 2022, 13
[42] Immune Checkpoint PD-1/PD-L1: Is There Life Beyond Antibodies?
Konstantinidou, Markella
Zarganes-Tzitzikas, Tryfon
Magiera-Mularz, Katarzyna
Holak, Tad A.
Domling, Alexander
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, 2018, 57 (18) : 4840 - 4848
[43] PD-L1 SNPs as biomarkers to define benefit in patients with advanced NSCLC treated with immune checkpoint inhibitors
Minari, Roberta
Bonatti, Francesco
Mazzaschi, Giulia
Dodi, Alessandra
Facchinetti, Francesco
Gelsomino, Francesco
Cinquegrani, Gloria
Squadrilli, Anna
Bordi, Paola
Buti, Sebastiano
Bersanelli, Melissa
Leonetti, Alessandro
Cosenza, Agnese
Ferri, Leonarda
Rapacchi, Elena
Quaini, Federico
Ardizzoni, Andrea
Tiseo, Marcello
TUMORI JOURNAL, 2022, 108 (01): : 47 - 55
[44] Macrocyclic Peptide Inhibitor of PD-1/PD-L1 Immune Checkpoint
Magiera-Mularz, Katarzyna
Kuska, Katarzyna
Skalniak, Lukasz
Grudnik, Przemyslaw
Musielak, Bogdan
Plewka, Jacek
Kocik, Justyna
Stec, Malgorzata
Weglarczyk, Kazimierz
Sala, Dominik
Wladyka, Benedykt
Siedlar, Maciej
Holak, Tad A.
Dubin, Grzegorz
ADVANCED THERAPEUTICS, 2021, 4 (02)
[45] Characterization of PD-1/PD-L1 Immune Checkpoint Expression in Osteosarcoma
Hashimoto, Kazuhiko
Nishimura, Shunji
Akagi, Masao
DIAGNOSTICS, 2020, 10 (08)
[46] Autoimmune Bullous Skin Disorders with Immune Checkpoint Inhibitors Targeting PD-1 and PD-L1
Naidoo, Jarushka
Schindler, Katja
Querfeld, Christiane
Busam, Klaus
Cunningham, Jane
Page, David B.
Postow, Michael A.
Weinstein, Alyona
Lucas, Anna Skripnik
Ciccolini, Kathryn T.
Quigley, Elizabeth A.
Lesokhin, Alexander M.
Paik, Paul K.
Chaft, Jamie E.
Segal, Neil H.
D'Angelo, Sandra P.
Dickson, Mark A.
Wolchok, Jedd D.
Lacouture, Mario E.
CANCER IMMUNOLOGY RESEARCH, 2016, 4 (05) : 383 - 389
[47] Clinical outcomes of NSCLC patients experiencing early immune-related adverse events to PD-1/PD-L1 checkpoint inhibitors leading to treatment discontinuation
Russano, Marco
Cortellini, Alessio
Giusti, Raffaele
Russo, Alessandro
Zoratto, Federica
Rastelli, Francesca
Gelibter, Alain
Chiari, Rita
Nigro, Olga
De Tursi, Michele
Bracarda, Sergio
Gori, Stefania
Grossi, Francesco
Bersanelli, Melissa
Calvetti, Lorenzo
Di Noia, Vincenzo
Scartozzi, Mario
Di Maio, Massimo
Bossi, Paolo
Falcone, Alfredo
Citarella, Fabrizio
Pantano, Francesco
Ficorella, Corrado
Filetti, Marco
Adamo, Vincenzo
Veltri, Enzo
Pergolesi, Federica
Occhipinti, Mario Alberto
Nicolardi, Linda
Tuzi, Alessandro
Di Marino, Pietro
Macrini, Serena
Inno, Alessandro
Ghidini, Michele
Buti, Sebastiano
Aprile, Giuseppe
Lai, Eleonora
Audisio, Marco
Intagliata, Salvatore
Marconcini, Riccardo
Brocco, Davide
Porzio, Giampiero
Piras, Marta
Rijavec, Erika
Simionato, Francesca
Natoli, Clara
Tiseo, Marcello
Vincenzi, Bruno
Tonini, Giuseppe
Santini, Daniele
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2022, 71 (04) : 865 - 874
[48] INTRATUMORAL EXPRESSION OF PD-1/PD-L1 IMMUNE CHECKPOINT IN PATIENTS WITH HEPATOCELLULAR CARCINOMA
Baquerizo, Angeles
Vavinskaya, Vera
Rojas, Angela
Mhoyan, Anna
Romero-Gomez, Manuel
Sher, Linda
Madani, Bahar
Fisher, Jonathan
Schaffer, Randolph
Frenette, Catherine T.
Marsh, Christopher
HEPATOLOGY, 2019, 70 : 206A - 206A
[49] Clinical outcomes of NSCLC patients experiencing early immune-related adverse events to PD-1/PD-L1 checkpoint inhibitors leading to treatment discontinuation
Marco Russano
Alessio Cortellini
Raffaele Giusti
Alessandro Russo
Federica Zoratto
Francesca Rastelli
Alain Gelibter
Rita Chiari
Olga Nigro
Michele De Tursi
Sergio Bracarda
Stefania Gori
Francesco Grossi
Melissa Bersanelli
Lorenzo Calvetti
Vincenzo Di Noia
Mario Scartozzi
Massimo Di Maio
Paolo Bossi
Alfredo Falcone
Fabrizio Citarella
Francesco Pantano
Corrado Ficorella
Marco Filetti
Vincenzo Adamo
Enzo Veltri
Federica Pergolesi
Mario Alberto Occhipinti
Linda Nicolardi
Alessandro Tuzi
Pietro Di Marino
Serena Macrini
Alessandro Inno
Michele Ghidini
Sebastiano Buti
Giuseppe Aprile
Eleonora Lai
Marco Audisio
Salvatore Intagliata
Riccardo Marconcini
Davide Brocco
Giampiero Porzio
Marta Piras
Erika Rijavec
Francesca Simionato
Clara Natoli
Marcello Tiseo
Bruno Vincenzi
Giuseppe Tonini
Daniele Santini
Cancer Immunology, Immunotherapy, 2022, 71 : 865 - 874
[50] Bone metastases as predictors of treatment response and rapidly progressive disease in NSCLC patients on PD-1/PD-L1 immune checkpoint inhibitors (ICI).
Lau, Sally C. M.
Le, Lisa W.
Smith, Elliot Charles
Chan, Sze Wah Samuel
Ryan, Malcolm
Brown, M. Catherine
Hueniken, Katrina
Eng, Lawson
Patel, Devalben
Chen, RuiQi
Sung, Mike Ru
Zer, Alona
Bradbury, Penelope Ann
Ohashi, Pamela S.
Shepherd, Frances A.
Tsao, Ming Sound
Liu, Geoffrey
Leighl, Natasha B.
Sacher, Adrian G.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)

← 1 2 3 4 5 →